To The Moon

Hi how can i help you

Hims & Hers Q1 Showdown: Can the Novo Nordisk Partnership Shield HIMS From an FDA Compounding Ban? Hims & Hers ($HIMS) is set to report highly anticipated Q1 2026 earnings tomorrow after the closing bell, riding an explosive +37% monthly rally that completely defied the broader healthcare sector slump. With the FDA aggressively proposing to exclude key weight-loss molecules from its 503B compounding bulks list, retail bears are betting on a catastrophic revenue cliff. Meanwhile, Eli Lilly ($LLY) just surged 10% on a massive earnings beat, leaving traders wondering: is Hims about to follow Lilly to new highs, or are traders walking straight into a regulatory trap? Here is the data-driven breakdown of how the smart money is positioning for the print. 1️⃣ The FDA 503B Proposal & T

Hims & Hers:  The High Stakes Gamble for a Weight Loss Revolution  🌟🌟🌟The energy around $Hims & Hers Health Inc.(HIMS)$  right now is electric - a mix of raw excitement and hold your breath anxiety.  After watching $Eli Lilly(LLY)$  deliver a powerhouse earnings that sent its stock surging 10%, we are all asking the same question : Can HIMS do it too? It feels like we are standing on the edge of a fundamental shift.  While Lilly owns the crown of the innovator, Hims & Hers is playing a more emotive game - the game of access.  HIMS is betting that the miracle of weight loss should not be just for tho

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

Hims & Hers Q1 Showdown: Can the Novo Nordisk Partnership Shield HIMS From an FDA Compounding Ban? Hims & Hers ($HIMS) is set to report highly anticipated Q1 2026 earnings tomorrow after the closing bell, riding an explosive +37% monthly rally that completely defied the broader healthcare sector slump. With the FDA aggressively proposing to exclude key weight-loss molecules from its 503B compounding bulks list, retail bears are betting on a catastrophic revenue cliff. Meanwhile, Eli Lilly ($LLY) just surged 10% on a massive earnings beat, leaving traders wondering: is Hims about to follow Lilly to new highs, or are traders walking straight into a regulatory trap? Here is the data-driven breakdown of how the smart money is positioning for the print. 1️⃣ The FDA 503B Proposal & T

Hims & Hers:  The High Stakes Gamble for a Weight Loss Revolution  🌟🌟🌟The energy around $Hims & Hers Health Inc.(HIMS)$  right now is electric - a mix of raw excitement and hold your breath anxiety.  After watching $Eli Lilly(LLY)$  deliver a powerhouse earnings that sent its stock surging 10%, we are all asking the same question : Can HIMS do it too? It feels like we are standing on the edge of a fundamental shift.  While Lilly owns the crown of the innovator, Hims & Hers is playing a more emotive game - the game of access.  HIMS is betting that the miracle of weight loss should not be just for tho

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

Hi how can i help you